1.24  0.05 (4.2%)		05-12 16:00
Open: 1.28 High: 1.34 Volume: 119,897		Pre. Close: 1.19 Low: 1.24 Market Cap: 84(M)

Short term
Mid term
Targets	6-month :	1.62	1-year :	1.89
Resists	First :	1.38	Second :	1.62
Pivot price	1.25
Supports	First :	1.17	Second :	1.04
MAs	MA(5) :	1.2	MA(20) :	1.26
	MA(100) :	1.55	MA(250) :	4.32
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	20	D(3) :	14.6
RSI	RSI(14): 48.1
52-week	High :	9.57	Low :	1.04

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CLYM ] has closed above bottom band by 41.7%. Bollinger Bands are 64.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 87 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.34 - 1.35	1.35 - 1.35
Low:	1.23 - 1.23	1.23 - 1.24
Close:	1.23 - 1.24	1.24 - 1.25

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Thu, 08 May 2025
Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB - The Malaysian Reserve

Thu, 08 May 2025
Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB - Quantisnow

Fri, 18 Apr 2025
Climb Bio Inc (NASDAQ: CLYM): On Track To A Higher Share Price - Stocksregister

Tue, 01 Apr 2025
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors - Yahoo Finance

Tue, 25 Feb 2025
Climb Bio to Present at Upcoming Investor Conferences - GlobeNewswire

Mon, 24 Feb 2025
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer - Yahoo

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	68 (M)
Shares Float	26 (M)
Held by Insiders	7.9 (%)
Held by Institutions	91 (%)
Shares Short	2,320 (K)
Shares Short P.Month	2,200 (K)

EPS	-1.53
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.15
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-10.4 %
Return on Equity (ttm)	-46.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-16 (M)
Levered Free Cash Flow	-10 (M)

PE Ratio	-0.82
PEG Ratio	0
Price to Book value	0.39
Price to Sales	0
Price to Cash Flow	-5.39

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.